David J. Halatek

David J. Halatek

Auto-generated profile, based on publicly available information

David J. Halatek

Department of Chemistry

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DHDavid J. Halatek
David J. Halatek
SBSarah A. Bo
Sarah A. Bo
SFSamuel M. Feder
Samuel M. Feder
LWLilly Wolf
Lilly Wolf
DCDylan J. Coffin
Dylan J. Coffin
UBUlrich Bierbach
Ulrich Bierbach

13 December 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
DHDavid Halatek
David Halatek
SBSarah Bo
Sarah Bo
SFSamuel Feder
Samuel Feder
LWLilly Wolf
Lilly Wolf
DCDylan Coffin
Dylan Coffin
UBUlrich Bierbach
Ulrich Bierbach
Platinum–acridine hybrid agents (PAs) represent a mechanistically unique class of DNA-targeted anticancer compounds with superior potency compared to cisplatin, but systemic toxicity has limited their clinical utility. To address this, we have developed platinum(IV) prodrugs of PAs for controlled reductive activation in tumor tissue. Short-chain fatty acid (SCFA) containing derivatives demonstrated to low-nanomolar cytotoxicity in cancer cells expressing human multi-drug and toxin extrusion protein 1 (hMATE1), consistent with rapid secondary active transporter-dependent uptake. Long-chain fatty acid (LCFA)-modified derivatives were less potent than the SCFA-based prodrugs in hMATE1high NCI-H460 (lung) and HepG2 (liver) cancer cells. Conversely, the LCFA derivatives, which target human serum albumin (HSA) and utilize the blood protein for cellular entry, showed an order of magnitude higher activity than the SCFA derivatives in hMATE1low HCT116 colon cancer cells. Together, these prodrug strategies hold promise of extending treatment with PAs to hMATE1-deficient cancers and improving the therapeutic window of the hybrid agents.